Thelansis’s "Intermediate or High-Risk Myelofibrosis (MF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Intermediate or High-Risk Myelofibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Intermediate or high-risk myelofibrosis (MF) is a malignant myeloproliferative neoplasm characterised by clonal haematopoietic stem cell proliferation, progressive bone marrow fibrosis, extramedullary haematopoiesis, and cytopenias. Driver mutations in JAK2, CALR, or MPL constitutively activate JAK-STAT signalling, propagating inflammatory cytokine dysregulation and stromal remodelling. Risk stratification using DIPSS-Plus or MIPSS70 incorporates clinical, cytogenetic, and molecular variables to guide therapeutic intensity. Patients present with profound fatigue, symptomatic splenomegaly, constitutional symptoms — drenching night sweats, fever, weight loss — and transfusion-dependent anaemia. Diagnosis integrates bone marrow biopsy demonstrating reticulin fibrosis, peripheral blood leukoerythroblastosis, and mutation profiling. JAK1/2 inhibitors — ruxolitinib and fedratinib — are first-line therapies, meaningfully reducing spleen volume and symptom burden; pacritinib and momelotinib address patients with significant thrombocytopaenia or anaemia respectively. Allogeneic stem cell transplantation remains the only potentially curative option, reserved for eligible intermediate-2 and high-risk patients. Management demands regular haematological monitoring, transfusion support, and thrombosis vigilance, with patient-centred symptom assessment and timely transplant evaluation central to optimising survival and quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Intermediate or High-Risk Myelofibrosis (MF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Intermediate or High-Risk Myelofibrosis (MF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.